The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25
   PubMed Web of Science ®Google Scholar
• D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(suppl 4):iv68-70
   Google Scholar
• Scagliotti G, Hanna N, Fossella F, The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-63
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010. [Epub ahead of print]
   Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91
   PubMed Web of Science ®Google Scholar
• Rossi A, Galetta D, Gridelli C. Biological prognostic and predictive factors in lung cancer. Oncology 2009;77(suppl.1):90-6
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Modifying IG. F1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007;6:821-33
   PubMed Web of Science ®Google Scholar
• Denley A, Cosgrove LJ, Booker GW, Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2005;16:421-39
   PubMed Web of Science ®Google Scholar
• Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008;19:111-20
   PubMed Web of Science ®Google Scholar
• LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37
   PubMed Web of Science ®Google Scholar
• Pandini G, Frasca F, Mineo R, Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277:39684-95
   PubMed Web of Science ®Google Scholar
• Brown J, Delaine C, Zaccheo OJ, Structure and functional analysis of the IGF-II/IGF2R interaction. EMBO J 2008;27:265-76
   PubMed Web of Science ®Google Scholar
• Oh SH, Lee OH, Schroeder CP, Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 2006; 5:2685-95
   PubMed Web of Science ®Google Scholar
• Myers MG Jr, Grammer TC, Wang LM, Insulin receptor substrate-1 mediates phosphatidylinositol 39-kinase and p70S6K signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem 1994;269:28783-9
   PubMed Web of Science ®Google Scholar
• Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006;94:465-8
   PubMed Web of Science ®Google Scholar
• Zhang X, Kamaraju S, Hakuno F, Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 2004;83:161-70
   PubMed Web of Science ®Google Scholar
• Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34
   PubMed Web of Science ®Google Scholar
• LeRoith D, Werner H, Beitner-Johnson D, Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143-63
   PubMed Web of Science ®Google Scholar
• Baserga R, Hongo A, Rubini M, The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997;1332:F105-26
   PubMed Web of Science ®Google Scholar
• Dudek H, Datta SR, Franke TF, Regulation of neuronal survival by the serine-threonine protein kinase akt. Science 1997;275:661-5
   PubMed Web of Science ®Google Scholar
• Kennedy SG, Wagner AJ, Conzen SD, The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997;11:701-13
   PubMed Web of Science ®Google Scholar
• Khwaja A, Rodriguez-Viciana P, Wennstrom S, Matrix adhesion and ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997;16:2783-93
   PubMed Web of Science ®Google Scholar
• Kulik G, Klippel A, Weber MJ. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-606
   PubMed Web of Science ®Google Scholar
• Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004;29:233-42
   PubMed Web of Science ®Google Scholar
• Peruzzi F, Prisco M, Dews M, Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999;19:7203-15
   PubMed Web of Science ®Google Scholar
• Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor I inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 1997;272:154-61
   PubMed Web of Science ®Google Scholar
• Pronk GJ, McGlade J, Pellicci G, Insulin-induced phosphorylation of the 46- and 52-kDa Shc proteins. J Biol Chem 1993;268:5748-53
   PubMed Web of Science ®Google Scholar
• Sasaoka T, Draznin B, Leitner WJ, Shc is the predominant signaling molecule coupling insulin receptors to activation of guanine nucleotide releasing factor and p21ras-GTP formation. J Biol Chem 1994;269:10734-8
   PubMed Web of Science ®Google Scholar
• Sasaoka T, Rose DW, Jhun BH, Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem 1994;269:13689-94
   PubMed Web of Science ®Google Scholar
• Yu H, Spitz MR, Mistry J, Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6
   PubMed Web of Science ®Google Scholar
• London SJ, Yuan JM, Travlos GS, Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 2002;94:749-54
   PubMed Web of Science ®Google Scholar
• Chang YS, Wang L, Liu D, Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;8:3669-75
   PubMed Web of Science ®Google Scholar
• Ullrich A, Gray A, Tam AW, Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503-12
   PubMed Web of Science ®Google Scholar
• Favelyukis S, Till JH, Hubbard SR, Miller WT. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001;8:1058-63
   PubMedGoogle Scholar
• Garber K. IGF-1: old growth factor shines as new drug target. J Natl Cancer Inst 2005;97:790-2
   PubMed Web of Science ®Google Scholar
• Karp DD, Pollak MN, Cohen RB, Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009;4:1397-403
   PubMed Web of Science ®Google Scholar
• Karp DD, Paz-Ares LG, Novello S, Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-22
   PubMed Web of Science ®Google Scholar
• Merrick DT, Dziadziuszko R, Szostakiewicz B, High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts) [abstract 7550]. J Clin Oncol 2007;25(18S):397s
   Google Scholar
• Available from: http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp (accessed on January 6, 2010)
   Google Scholar
• Available from: http://www.cancer.gov/ (accessed on February 26, 2010)
   Google Scholar
• Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:11637
   Web of Science ®Google Scholar
• van der Veeken J, Oliveira S, Schiffelers RM, Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009;9:748-60
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Toschi L, Tallini G, Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006;17:1120-7
   PubMed Web of Science ®Google Scholar
• Ludovini V, Bellezza G, Pistola L, High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 2009; 20:842-9
   PubMed Web of Science ®Google Scholar
• Gong Y, Yao E, Shen R, High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009;4:e7273
   PubMed Web of Science ®Google Scholar
• Rowinski EK, Youssoufian H, Tonra JR, IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13:5549s-55s
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Sarantopoulos J, Patnaik A, Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7
   PubMed Web of Science ®Google Scholar
• Atzori F, Tabernero J, Cervantes A, A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors [abstract 3519]. J Clin Oncol 2008;26(15S):157s
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Tirado Gomez M, Lewis N, A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule [abstract 3520]. J Clin Oncol 2008;26(15S):158s
   Google Scholar
• Moreau P, Hulin C, Facon T, Phase I study of AVE1642 anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Blood 2007;110:1166
   Google Scholar
• Tolcher AW, Patnaik A, Till E, A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumor (ST) [abstract 3582]. J Clin Oncol 2008;26(15S):173s
   Google Scholar
• Wang Y, Lipari P, Wang X, A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 2010;9:410-8
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 2008;3:815-8
   PubMed Web of Science ®Google Scholar